Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations

Background: The BRAF V600E mutation, found in up to 12% of patients with metastatic colorectal cancer, is associated with aggressive disease and poor response to standard chemotherapy. However, the advent of BRAF inhibitors has led to improved clinical outcomes and survival. While surrogate endpoint...

詳細記述

書誌詳細

主要な著者:	J. Ros, V. Navarro, G. Villacampa, I. Baraibar, F. Salvà, M. Rodriguez, C. Vaghi, A. Garcia, A. Alcaraz, J. Tabernero, E. Élez, R. Dienstmann
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2025-09-01
シリーズ:	ESMO Gastrointestinal Oncology
主題:	surrogate markers BRAF mutation colorectal cancer targeted therapy BRAF inhibitor
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2949819825000949
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!